TD Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.82M | Buy |
202,482
+27,788
| +16% | +$799K | 0.01% | 749 |
|
|
2025
Q1 | $5.86M | Sell |
174,694
-54,310
| -24% | -$1.82M | 0.01% | 761 |
|
|
2024
Q4 | $11.7M | Buy |
229,004
+18,882
| +9% | +$965K | 0.01% | 624 |
|
|
2024
Q3 | $10.7M | Buy |
210,122
+5,124
| +2% | +$260K | 0.01% | 630 |
|
|
2024
Q2 | $9.18M | Sell |
204,998
-30,200
| -13% | -$1.35M | 0.01% | 633 |
|
|
2024
Q1 | $11M | Buy |
235,198
+58,772
| +33% | +$2.75M | 0.01% | 609 |
|
|
2023
Q4 | $6.28M | Buy |
176,426
+37,000
| +27% | +$1.32M | 0.01% | 706 |
|
|
2023
Q3 | $4.15M | Buy |
139,426
+80,526
| +137% | +$2.39M | 0.01% | 774 |
|
|
2023
Q2 | $1.06M | Buy |
58,900
+31,300
| +113% | +$564K | ﹤0.01% | 1119 |
|
|
2023
Q1 | $443K | Buy |
+27,600
| New | +$443K | ﹤0.01% | 1283 |
|
|
2019
Q3 | – | Sell |
-8,419
| Closed | -$210K | – | 1340 |
|
|
2019
Q2 | $210K | Buy |
+8,419
| New | +$210K | ﹤0.01% | 1294 |
|
|
2019
Q1 | – | Sell |
-9,619
| Closed | -$288K | – | 1346 |
|
|
2018
Q4 | $288K | Sell |
9,619
-1,300
| -12% | -$38.9K | ﹤0.01% | 1309 |
|
|
2018
Q3 | $313K | Buy |
+10,919
| New | +$313K | ﹤0.01% | 1363 |
|